← Leaderboards
Benson Edagwa
University Of Nebraska Medical Center
$6,144,379
Attributed
$13,145,057
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,145,057 · 6
By mechanism
R01$11,196,580 · 4
R61$1,228,661 · 1
R56$719,816 · 1
Top collaborators
- Howard Eliot Gendelman14 shared
- Natalia Aleksandr Osna4 shared
- Larisa Y Poluektova3 shared
- Sudipta Panja1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Natalia Aleksandr Osna$4,604,885
- Larisa Y Poluektova$9,010,153
- Sudipta Panja$245,345
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsAnti-Retroviral AgentsSafetyFormulationPharmaceutical PreparationsMacrophageProdrugsHumanized MouseDrug KineticsMedicineDoseNanocrystalAdherencePreventionLipophilicityTenofovirInfectionHiv-1SiteUptakePharmacokinetics And PharmacodynamicsIntramuscular InjectionsTreatment ProtocolsNanomedicine
Grant awards (18)
Dose flexible ultra-long-acting prodrug formulations for pediatric populations$1,228,661
R61 · FY2025 · AI · contact PI
Prodrug Formulations Create Sustained-Release Antiretrovirals$744,473
R01 · FY2025 · AI · contact PI
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirs$736,036
R01 · FY2025 · MH
LASER ART for PreP$698,744
R01 · FY2025 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B$611,174
R01 · FY2025 · AI
LASER ART for PreP$698,744
R01 · FY2024 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B$611,174
R01 · FY2024 · AI
Prodrug Formulations Create Sustained Release Antiretrovirals$757,138
R01 · FY2023 · AI · contact PI
LASER ART for PreP$698,743
R01 · FY2023 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B$611,174
R01 · FY2023 · AI
Prodrug Formulations Create Sustained Release Antiretrovirals$757,138
R01 · FY2022 · AI · contact PI
LASER ART for PreP$698,307
R01 · FY2022 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B$610,511
R01 · FY2022 · AI
Prodrug Formulations Create Sustained Release Antiretrovirals$757,138
R01 · FY2021 · AI · contact PI
LASER ART for PreP$710,244
R01 · FY2021 · AI
Prodrug Formulations Create Sustained Release Antiretrovirals$747,921
R01 · FY2020 · AI · contact PI
Prodrug Formulations Create Sustained Release Antiretrovirals$747,921
R01 · FY2019 · AI · contact PI
Chemical, Nanomedicine and Autophagy Strategies to Create Sustained-Release Antiretroviral Products$719,816
R56 · FY2018 · AI